Incyte, TG's PI3K Inhibitors Show Safety Advantage In Indolent NHL
Data At ASH Show Strong Efficacy, Favorable Safety For Umbralisib, Parsaclisib
Incyte and TG Therapeutics presented Phase II data on their PI3K inhibitors at ASH. • Source: Shutterstock 
